Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD

Labeling adds two of the company’s most widely used high voltage devices into MRI-compatible portfolio

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD

January 3, 2018 — Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) and Fortify Assura implantable cardioverter defibrillator (ICD). The approvals follow recent MR-conditional labeling approvals for the Assurity MRI pacemaker, Ellipse ICD and associated MRI-compatible leads, and further expand Abbott's portfolio of MRI-ready devices for patients indicated for ICDs and/or CRT-D devices who may need an MRI in the future.

Physicians utilize ICDs to restore normal heart rhythms in patients at risk for experiencing potentially life-threatening heart rhythms; they implant CRT-D devices to help the lower chambers of the heart beat in rhythm in patients battling progressive congestive heart failure and improve blood flow throughout the body. For some patients, the potential need for a future MRI has made MR-conditional labeling important as physicians assess therapies and device options. As a result, Abbott has done extensive testing to demonstrate that these devices are safe in the most commonly-used MRI scanners.

In addition to MRI compatibility, Abbott's Fortify Assura ICD and Quadra Assura MP CRT-D also include the company's suite of TailoredTherapy features, which are designed to provide physicians additional flexibility and control in how they deliver therapy to treat their patient's cardiac arrhythmias and congestive heart failure, even as their patient's therapy needs change over time. With the TailoredTherapy feature set, the Fortify Assura ICD and Quadra Assura MP CRT-D help protect against the delivery of unnecessary therapy and continuously evaluate the condition of a lead to consistently deliver appropriate therapy. Combined with MRI compatibility, these features offer physicians additional options to leverage when managing patient care.

The Quadra Assura MP CRT-D also offers Abbott's proprietary MultiPoint Pacing and SyncAV technology to provide additional options for CRT patients who are not responsive to traditional cardiac resynchronization therapy. With MultiPoint Pacing, Abbott allows physicians to "individualize" cardiac resynchronization therapy and shift their patient's treatment options from a single point of pacing to multiple options to better deliver therapy where needed. Abbott's SynvAV software allows a CRT device to detect real-time changes in a patient's cardiac condition and adjust therapy accordingly.

As with all Abbott cardiac rhythm management devices, all therapy data captured by the Fortify Assura and Quadra Assura MP devices can be directly, securely and wirelessly sent to a patient's doctor through the Merlin.netTM Patient Care Network. This communication allows physicians to remotely monitor their patient's therapy and assess any need for intervention.

For more information: www.sjm.com

Related Content

Abbott Receives FDA Approval for MR-Conditional Labeling of Assurity Pacemaker

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD

St. Jude Medical Announces U.S. Launch, Implants of MultiPoint Pacing

St. Jude Medical Expands Heart Failure Portfolio with SyncAV CRT Technology

Related Content

A comparison of color-flow Doppler cardiac ultrasound showing blood flow, and blood speckle tracking revealing a more detailed and complex understanding of the low. It shows the formation of a vortex that may play a role in future assessments for the efficiency of flow in the heart and vessels. #ASE21 #ASE2021 #Vectorflowimaging

A comparison of color-flow Doppler cardiac ultrasound showing blood flow, and blood speckle tracking revealing a more detailed and complex understanding of the flow. It shows the formation of a vortex that may play a role in future assessments for the efficiency of flow in the heart and vessels. Image from JASE, read more.

Feature | Cardiac Imaging | August 17, 2021 | By Dave Fornell, Editor
In the past several years, a few ca...
A cardiac MRI of athletes who had COVID-19 is seven times more effective in detecting inflammation of the heart than symptom-based testing, according to a study led by researchers at The Ohio State University Wexner Medical Center and College of Medicine with 12 other Big Ten programs.

Cardiac Magnetic Resonance Imaging in Athletes With Clinical and Subclinical Myocarditis A-D, Athlete A with subclinical possible myocarditis was asymptomatic with normal electrocardiogram (ECG), echocardiogram, and high-sensitivity troponin findings. A, T2 mapping showing elevated T2 in basal-mid inferolateral wall in short axis view. B, late gadolinium enhancement (LGE) in the basal inferolateral wall in short axis view. C, Postcontrast steady state-free precession (SSFP) images showing contrast uptake in the basal-mid inferolateral wall in short axis view. D, LGE in the inferolateral wall in 3-chamber view. E-H, Athlete B with subclinical probable myocarditis was asymptomatic with normal ECG, normal echocardiogram, and elevated high-sensitivity troponin findings. E, T2 mapping showing elevated T2 in the anteroseptal wall in short axis view. F, LGE in the anteroseptal wall in 3-chamber view. G, T2 mapping showing elevated T2 in the anteroseptal wall in 3-chamber view. F, Postcontrast SSFP image showing pericardial effusion in short axis view. I-K, Athlete C with clinical myocarditis and chest pain, dyspnea, abnormal ECG, normal echocardiogram, and normal troponin findings. I, T2 mapping showing elevated T2 in the lateral wall short axis view. J, Postcontrast SSFP images showing contrast uptake in midlateral wall in short axis view. K, LGE in the epicardial midlateral wall in short axis view. L-N, Athlete D with clinical myocarditis, chest pain, abnormal ECG, echocardiogram, and troponin findings. L, T1 mapping showing elevated native T1 in midlateral wall in short axis view. M, T2 mapping showing elevated T2 in the midlateral wall in short axis view. N, LGE in the epicardial midlateral wall in short axis view. IR indicates inferior right view; IRP, inferior, right, posterior view; PLI, posterior, left, inferior view; SL, superior left view; SLA, superior, left, anterior view. Image courtesy of JAMA Cardiol. Published online May 27, 2021. doi:10.1001/jamacardio.2021.2065

News | Cardiac Imaging | June 15, 2021
June 15, 2021 — A...
Rensselaer algorithm can identify risk of cardiovascular disease using lung cancer scan #CT
News | Cardiac Imaging | June 14, 2021
June 14, 2021 — Heart disease and cancer are the ...
Women’s Heart Attack Research Program (HARP) shows combining OCT and cardiac MRI can detect the underlying cause of heart attack in women who did not have blocked arteries

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | November 17, 2020
November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many wome
An example of a CT coronary artery calcium scoring exam showing how each vessel segment is scored to assess a patient's risk for a future heart attack. Example is from Philips Healthcare.

An example of a CT coronary artery calcium scoring exam showing how each vessel segment is scored to assess a patient's risk for a future heart attack. Example is from Philips Healthcare.

News | Cardiac Imaging | September 25, 2020
September 25, 2020 — A study out of University Hospitals (UH) found that removing the cost barrier for coronary arter
Rafael Rivero, M.D., Global Head of Medical Affairs at MSI, said: "The importance of MyoStrain cannot be understated because of the test's immense clinical value and ability to quantify intramyocardial dysfunction across 48 segments of the heart. In a six-heartbeat MRI scan, MyoStrain arms physicians with novel clinical information about a patient's heart health."
News | Cardiac Imaging | August 11, 2020
August 11, 2020 — Myocardial Solutions, Inc. and United Imaging, Inc.
The Mindways Solid phantom with volume of interest in the quality assurance phantom (red circles, left side). A participant's noncontrast-enhanced axial CT (right side) with volume of interest (yellow circles) in the trabecular bone compartment of three vertebrae for bone mineral density measurements. Image courtesy of Radiological Society of North America

The Mindways Solid phantom with volume of interest in the quality assurance phantom (red circles, left side). A participant's noncontrast-enhanced axial CT (right side) with volume of interest (yellow circles) in the trabecular bone compartment of three vertebrae for bone mineral density measurements. Image courtesy of Radiological Society of North America

News | Cardiac Imaging | July 15, 2020
July 15, 2020 — ...